At a Churchill Club event on July 13, entitled "Stem Cell Research: The Hope, the Reality & the Future," Silicon Valley VCs, a biopharmaceutical executive and a pioneering stem cell scientist discussed the controversial topic. With the passage of Proposition 71 in November, the California Institute for Regenerative Medicine has been tapped to distribute nearly $300 million annually in stem cell funds for 10 years to California universities and research institutions. Moderator Sam Colella, managing director of Versant Ventures and Chair of Stanford's Bio-X-BioEngineering Advisory Board, hosted the panelists, including:
Brook Byers, Partner, Kleiner Perkins Caufield & Byers; Board Member Stanford's Bio-X-BioEngineering Advisory Board
Michael Goldberg, General Partner, Mohr Davidow Ventures; Board Member, California Institute of Regenerative Medicine
Thomas B. Okarma, Ph.D., M.D., President & Chief Executive Officer, Geron, Inc.
Irving L. Weissman, M.D., Director, Institute for Cancer/Stem Cell Biology and Medicine; Director, Comprehensive Cancer Center; Director, Program in Regenerative Medicine; Professor of Pathology and Developmental Biology, Stanford University School of Medicine
An audiocast of the panel is available as an MP3 that can be downloaded or, if you’re already subscribed to ZDNet’s IT Matters series of audio podcasts, it will show up on your system or MP3 player automatically (See ZDNet’s podcasts: How to tune in).